RxDoctor Payments Data

Mona Elsayed, MD

Clinical Neurophysiology · Grand Rapids, MINPI 1316118912

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.7% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Neuropace, Inc. at 30.2% of the total.

$558in general payments, 2019–2025

Across 16 payments — averaging $34.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neuropace, Inc.$169
  • E.r. Squibb & Sons, L.L.C.$107
  • Jazz Pharmaceuticals Inc.$105
  • Novartis$67
  • Aucta Pharmaceuticals, Inc.$34
  • UCB, Inc.$31
  • plus $47 from 3 others

What the payments were for

  • Food & beverage$54698%
  • Education$132%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in Michiganto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$42,477
Medicare patients
210
Services billed
345

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam29$52,055
AptiomEslicarbazepine Acetate12$29,387
Lamotrigine ErLamotrigine28$8,459
Lacosamide124$6,199
Clobazam86$4,298
Oxcarbazepine47$3,414
Carbamazepine ErCarbamazepine52$3,187
Levetiracetam102$2,859
Topiramate75$1,262
Phenytoin Sodium Extended34$1,226
Levetiracetam ErLevetiracetam12$1,041
Lamotrigine52$1,040
Phenobarbital22$615
Gabapentin33$549
Divalproex Sodium21$372

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact$31$52,05529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Michiganon file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →